Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DY67HC
|
|||
| Drug Name |
Efinopegdutide
|
|||
| Synonyms |
MK-6024
Click to Show/Hide
|
|||
| Drug Type |
Peptide
|
|||
| Indication | Non-alcoholic steatohepatitis [ICD-11: DB92.1; ICD-10: K75.8; ICD-9: 571.8] | Phase 2 | [1] | |
| Company |
Merck
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucagon receptor (GCGR) | Target Info | Agonist | [2] |
| Glucagon-like peptide 1 receptor (GLP1R) | Target Info | Agonist | [2] | |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Insulin secretion | ||||
| Glucagon signaling pathway | ||||
| Reactome | Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | |||
| G alpha (s) signalling events | ||||
| Glucagon-type ligand receptors | ||||
| Glucagon signaling in metabolic regulation | ||||
| G alpha (q) signalling events | ||||
| WikiPathways | GPCRs, Class B Secretin-like | |||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04944992) A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver Disease. U.S.National Institutes of Health. | |||
| REF 2 | Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. Expert Opin Emerg Drugs. 2021 Sep;26(3):231-243. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.